Valneva SE

VALNEVA - Declaration of shares and voting rights: November 30, 2022

05 Dec 2022 12:00:00 By Nasdaq GlobeNewswire

Valneva Reports Positive 12-Month Antibody Persistence Data for Single-Shot Chikungunya Vaccine Candidate

05 Dec 2022 01:00:00 By Nasdaq GlobeNewswire

Valneva to Host Investor Day in New York City

29 Nov 2022 12:00:00 By Nasdaq GlobeNewswire

Valneva Appoints Dipal Patel as Chief Commercial Officer

17 Nov 2022 01:00:00 By Nasdaq GlobeNewswire

Valneva Reports Nine-Month 2022 Results and Provides Corporate Updates

10 Nov 2022 01:00:00 By Nasdaq GlobeNewswire

Valneva to Present and Hold Investor Meetings at the Jefferies London Healthcare Conference

07 Nov 2022 11:45:00 By Nasdaq GlobeNewswire

VALNEVA - Declaration of shares and voting rights: October 31, 2022

04 Nov 2022 13:00:00 By Nasdaq GlobeNewswire

Valneva to Present on its Single-Shot Chikungunya Vaccine Candidate at Leading Scientific Conferences

10 Oct 2022 01:00:00 By Nasdaq GlobeNewswire

VALNEVA - Declaration of shares and voting rights: Interim status at October 4, 2022 (and information at September 30, 2022)

07 Oct 2022 12:00:00 By Nasdaq GlobeNewswire

Valneva Announces Closing of Upsized €102.9 Million Global Offering

04 Oct 2022 16:00:00 By Nasdaq GlobeNewswire

Valneva Announces Pricing of €102.9 Million Global Offering of American Depositary Shares and Ordinary Shares

30 Sep 2022 01:11:36 By Nasdaq GlobeNewswire

Valneva Announces Launch of Approximately $40 Million in a Proposed Global Offering of American Depositary Shares and Ordinary Shares

28 Sep 2022 17:43:47 By Nasdaq GlobeNewswire

Valneva Provides Further Update on its COVID-19 Activities

26 Sep 2022 01:00:00 By Nasdaq GlobeNewswire

Valneva and IDT Biologika Agree on Termination of their COVID-19 Collaboration

16 Sep 2022 16:30:00 By Nasdaq GlobeNewswire

Valneva and VBI Vaccines Announce European Partnership for Marketing and Distribution of PreHevbri®

08 Sep 2022 01:00:00 By Nasdaq GlobeNewswire

Valneva Announces Publication of its COVID-19 Vaccine Phase 3 Data in The Lancet Infectious Diseases

06 Sep 2022 01:00:00 By Nasdaq GlobeNewswire

VALNEVA - Declaration of shares and voting rights: August 31, 2022

05 Sep 2022 12:00:00 By Nasdaq GlobeNewswire

Valneva Reports Further Positive Phase 3 Immunogenicity and the First Heterologous Booster Results for its Inactivated, Adjuvanted COVID-19 Vaccine VLA2001

29 Aug 2022 01:00:00 By Nasdaq GlobeNewswire

Valneva Confirms WHO Recommendations for its Inactivated COVID-19 Vaccine

23 Aug 2022 11:45:00 By Nasdaq GlobeNewswire

Valneva Initiates Rolling Submission of FDA Biologics License Application for its Single-Shot Chikungunya Vaccine Candidate

18 Aug 2022 12:00:00 By Nasdaq GlobeNewswire